On Tuesday 7th February Volteface will be publishing ‘Black Sheep: An investigation into Existing Support for Problematic Cannabis Use’
We invited Paul Hayes, the CEO of Collective Voice, to share his perspective on the state of cannabis abuse in the UK.
Just over 2 million adults in England will use cannabis this year. Most will do so occasionally, slotting their cannabis use into otherwise unremarkable lives, just as an even larger slice of the population will do with alcohol.
The lack of harm accruing to most cannabis users drives the debate for reform of the Misuse of Drugs Act. If the majority of users suffer no long-term harm then what right does the state have to interfere in their private pursuit of pleasure, particularly as the enforcement of the current law can result in criminal sanctions that potentially do more damage to young people’s future prospects than is likely to flow from their drug use.
So far, so familiar, but what about the minority whose use is not about occasional controlled pleasure, but daily damaging dependence? Clearly there are cogent arguments to be made for reform, but its advocates won’t help their cause and their assumption of the moral high ground if they continue to ignore the following “inconvenient truths”.
Levels of cannabis consumption vary dramatically; 54% of users will do so less than once a month, whilst 9% will have a pattern of daily use. The impact of cannabis use on the lives and prospects of these two groups is very different.
The daily users consume the vast majority of all the cannabis used in the country, 77% of the total.
The occasional users collectively consume 1% of the total market.
The largely benign experience of the articulate, well-educated and politically active majority dominates the media debate about cannabis while the negative experience of the invisible, marginalised and vulnerable minority is ignored, or even denied.
Inevitably, frequency and intensity of use is closely associated with the onset of dependence, with one quarter (24%) of all intensive users fulfilling the criteria for severe dependence.
Those whose use becomes problematic are not a random subset of the entire cannabis using population.
Unlike the stable recreational users, they will tend to be drawn from those with the fewest social and economic supports, the most fragile mental health, and a range of complex overlapping social and health problems.
Cannabis dependence has now replaced heroin as the primary drug of misuse for those aged 18 to 24 in treatment services, accounting for 54% of young adults in treatment, 7095 individuals.
Most individuals refer themselves to treatment and derive significant benefit from the intervention. Within six months, 38% of cannabis users in the non-opiate client group have chosen to stop using entirely with a further 17% reducing their use from an average 22 days per month to 11.
The negative consequences of cannabis use for the 60,000 people who enter treatment each year is not of itself the clinching argument for retention of the current law. However, anyone advocating reform, is in my view, under a moral obligation to explain how their new regime will deal with the impact on vulnerable sections of the population. There is, at the very least, a risk that the increased availability that will accompany a regulated market, will lead to increased use and increased harm among those least able to cope.
To date, advocates of regulated markets have focused their thinking on restricting access for children and devising a pricing and taxation regime that guarantees a revenue stream for entrepreneurs and the government, while undercutting the illicit market. To these challenges there needs to be added the further complexity of controlling a market which may well find, as the alcohol and tobacco markets have, that the most reliable way to grow their business is to target those groups who are least able to deal with the negative consequences of their products.
If this is the outcome, it may well be a blow for freedom, but I doubt it will make the world a better place.